Are you someone living with Parkinson's disease? If so, you are aware that in addition to symptoms affecting movement, people with Parkinson's disease also experience non-motor symptoms such as problems with mood and motivation which can be difficult to treat. If you have been living with Parkinson's disease for at least 5 years and take medication for Parkinson's disease, you may be eligible to participate in a research study aimed at treating low motivation with a form of non-invasive brain stimulation called transcranial magnetic stimulation (TMS).

Examine the validity and reliability of UTRS in the assessment of essential tremor (ET) and Parkinson tremor.

Are you between 18 and 45 years of age and diagnosed with multiple sclerosis, without MS relapses within the past year? Are you currently prescribed with MS medication? If so, you may be able to participate in a research study examining whether a switch to a high-efficacy medication- Ofatumumab, would work better for you than your current treatment.

The purpose of the current Phase 3 study is to confirm the effectiveness and safety of batoclimab in participants with generalized Myasthenia Gravis in 2 different doses of batoclimab compared to placebo.

Have you or a family member been diagnosed with Parkinson's Disease? Would you be interested in helping researchers learn more about Parkinson's by giving a blood or saliva sample? If so, you may be eligible to participate in a research study that will utilize genetic testing to provide you more information about the possible roles of your genes in your diagnosis.

In this study, we want to understand whether we can use non-invasive brain stimulation to treat non-moto symptoms like autonomic nervous system dysfunction and depression in people with Parkinson's disease.

To assess the safety, tolerability and manufacturing feasibility of Descartes-08 in patients with generalized Myasthenia Gravis

The purpose of this study is to identify and genomically-characterize individuals with genetically unexplained neurodevelopmental disorders, such as epilepsy. The overarching goal is to provide patients with improved information about the underlying genetic basis of their disorder and illuminate novel genetically-defined treatment approaches in the future.

If you have a child with MS who is between 10 and 18 years old who has experienced at least one MS episode in the last 12 months, or at least 2 episodes in the last 24 months, your child could qualify for a study testing a drug that is currently used to treat adults with MS.

The study is being done to compare two ways of treating patients with a brain injury. At this time medical providers do not know if one way is better than the other. Both ways of treating patients are used in standard of care. None of the treatments in this study are investigational.